Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway

Hepatology

Volumn 50, Issue 5, 2009, Pages 1370-1379

  Simonin, Yannick ^a,b   Disson, Olivier ^a,b,e   Lerat, Hervé ^a,b,f   Antoine, Etienne ^a,b   Binamé, Fabien ^a,b   Rosenberg, Arielle R ^c   Desagher, Solange ^a,b   Lassus, Patrice ^a,b   Bioulac Sage, Paulette ^d   Hibner, Urszula ^a,b  

^a CNRS   (France)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL PELLEGRIN   (France)

^e INSTITUT PASTEUR   (France)

^f HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; CALPASTATIN; CYSTEINE PROTEINASE; DEATH RECEPTOR; NONSTRUCTURAL PROTEIN 5A; PROTEIN BID; VIRUS PROTEIN; VIRUS RNA;

ADULT; AGED; ANIMAL CELL; ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REPLICON; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ADULT; AGED; ANIMALS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CALPAIN; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; REPLICON; SIGNAL TRANSDUCTION; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 72949108464     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23169     Document Type: Article

References (39)

1. Hoofnagle JH. Course and outcome of hepatitis C. HEPATOLOGY 2002;36:S21-S29.
2. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006;25:3834-3847.
3. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002;122:352-365.
4. Disson O, Haouzi D, Desagher S, Loesch K, Hahne M, Kremer EJ, et al. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2004;126:859-872.
5. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996;24:289-293.
6. Raser KJ, Posner A, Wang KK. Casein zymography: a method to study mu-calpain, m-calpain, and their inhibitory agents. Arch Biochem Biophys 1995;319:211-216.
7. Arthur JS, Mykles DL. Calpain zymography with casein or fluorescein isothiocyanate casein. Methods Mol Biol 2000;144:109-116.
8. Conover WJ. Practical non parametric statistics. London, UK: Wiley; 1971.
9. Keasler VV, Lerat H, Madden CR, Finegold MJ, McGarvey MJ, Mohammed EM, et al. Increased liver pathology in hepatitis C virus transgenic mice expressing the hepatitis B virus X protein. Virology 2006;347:466-475.
10. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002;8:10-20.
11. Lau DT, Fish PM, Sinha M, Owen DM, Lemon SM, Gale M Jr. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. HEPATOLOGY 2008;47:799-809.
12. De Mitri MS, Poussin K, Baccarini P, Pontisso P, D'Errico A, Simon N, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413-415.
13. McGivernDR,Lemon SM.Tumorsuppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol 2008;4:399-415.
14. Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. HEPATOLOGY 2006;43:S145-S150.
15. Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genomelength dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002;76:2997-3006.
16. Yin XM. Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene 2006;369:7-19.
17. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003;83:731-801.
18. Porn-Ares MI, Samali A, Orrenius S. Cleavage of the calpain inhibitor, calpastatin, during apoptosis. Cell Death Differ 1998;5:1028-1033.
19. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61.
20. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.
21. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005;102:9294-9299.
22. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006;103:7408-7413.
23. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-945.
24. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008;128:133-147.
25. Fischer R, Baumert T, Blum HE. Hepatitis C virus infection and apoptosis. World J Gastroenterol 2007;13:4865-4872.
26. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346.
27. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-S50.
28. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 2000;275:21648-21652.
29. Mehdi S, Angelastro MR, Wiseman JS, Bey P. Inhibition of the proteolysis of rat erythrocyte membrane proteins by a synthetic inhibitor of calpain. Biochem Biophys Res Commun 1988;157:1117-1123.
30. Tamai M, Matsumoto K, Omura S, Koyama I, Ozawa Y, Hanada K. In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64. J Pharmacobiodyn 1986;9:672-677.
31. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004;85:2485-2502.
32. Waris G, Livolsi A, Imbert V, Peyron JF, Siddiqui A. Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. J Biol Chem 2003;278:40778-40787.
33. Pujol FH, Devesa M. Genotypic variability of hepatitis viruses associated with chronic infection and the development of hepatocellular carcinoma. J Clin Gastroenterol 2005;39:611-618.
34. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. HEPATOLOGY 2007;46:1350-1356.
35. Chen M, He H, Zhan S, Krajewski S, Reed JC, Gottlieb RA. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J Biol Chem 2001;276:30724-30728.
36. Miyasaka Y, Enomoto N, Kurosaki M, Sakamoto N, Kanazawa N, Kohashi T, et al. Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-alpha-mediated apoptosis in Huh7 cells. J Infect Dis 2003;188:1537-1544.
37. Wilson TJ, Singh RK. Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim Biophys Acta 2008;1785:85-95.
38. Yu CG, Joshi A, Geddes JW. Intraspinal MDL28170 microinjection improves functional and pathological outcome following spinal cord injury. J Neurotrauma 2008;25:833-840.
39. Huang Y, de Morree A, van Remoortere A, Bushby K, Frants RR, Dunnen JT, et al. Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. Hum Mol Genet 2008;17:1855-1866.